Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 12 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The revision reflects prescription prices in the dispensing pharmacy business remaining above plan for both drug and technical fees, the continued benefits from the efficient use of rental equipment in the silver business from the previous fiscal year, the expected continuation of strong performance in the dispensing pharmacy business during the first half, and the inclusion in consolidation from the third quarter of QLCプロデュース株式会社, which became part of the group in July 2026.
| Item | Details |
|---|---|
| Net Sales | ¥165,400 million → ¥167,980 million（+1.6%） |
| Operating profit | ¥8,985 million → ¥10,286 million（+14.5%） |
| Ordinary income | ¥9,437 million → ¥10,716 million（+13.5%） |
| Profit attributable to owners of the parent | ¥6,117 million → ¥6,866 million（+12.2%） |
| Net income per share | 198.08 yen → 222.25 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Fiscal year ended March 2026: net sales of ¥159,664 million, operating income of ¥9,382 million, ordinary income of ¥10,098 million, net income attributable to owners of the parent of ¥6,069 million, and earnings per share of ¥185.61 |
| Reason for the revision | The revision reflects prescription prices in the dispensing pharmacy business remaining above plan for both drug and technical fees, the continued benefits from the efficient use of rental equipment in the silver business from the previous fiscal year, the expected continuation of strong performance in the dispensing pharmacy business during the first half, and the inclusion in consolidation from the third quarter of QLCプロデュース株式会社, which became part of the group in July 2026. |
| Dividend forecast revision | The year-end dividend has been increased from ¥40.00 per share to ¥49.00, and the annual dividend has been increased from ¥80.00 to ¥89.00. The second-quarter-end dividend remains unchanged at ¥40.00. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited prescription prices in the dispensing pharmacy business remaining above plan for both drug and technical fees, the continued benefits of efficient use of rental equipment in the silver business, the expected continuation of strong performance in the dispensing pharmacy business during the first half, and the consolidation of QLCプロデュース株式会社 from the third quarter following its addition to the group in July 2026.